Literature DB >> 9626342

A small deletion in the 3'-untranslated region of the cyclin D1/PRAD1/bcl-1 oncogene in a patient with chronic lymphocytic leukemia.

Y Hosokawa1, R Suzuki, T Joh, Y Maeda, S Nakamura, Y Kodera, A Arnold, M Seto.   

Abstract

The cyclin DI/PRAD1 oncogene, a key regulator of the G1 phase of the cell cycle, has been incriminated in the pathogenesis of human neoplasia. Cyclin D1 was also demonstrated to be identical to the long-sought bcl-1 oncogene in B-cell malignancies with the t(11;14)(q13;q32) translocation. We report here a small deletion in the 3'-untranslated portion of the cyclin D1 gene in leukemia cells of a patient diagnosed with B-chronic lymphocytic leukemia (CLL), associated with overexpression of the corresponding cyclin D1 mRNA. During a Northern blot survey of B-cell malignancies, we identified a patient whose CLL cells showed a marked increase in 1.5-1.6 kb cyclin D1 mRNA species. Subsequent Southern blot analysis showed that genomic DNA from the patient's cells contained an extra band in the EcoRI digest, suggesting that one allele of the cyclin D1 gene may be altered. Polymerase chain reaction (PCR) analysis of the genomic DNA and direct DNA sequencing clearly disclosed that one allele of the cyclin D1 gene was deleted in the 3'-untranslated region, which would contribute to an increased stability of its mRNA. Reverse transcription-polymerase chain reaction (RT-PCR) analysis and direct DNA sequencing revealed that the cyclin D1 mRNA was deleted at the corresponding region. This finding provides further evidence for a critical role of cyclin D1 in the pathogenesis of B-cell malignancies and highlights a novel mechanism, a small deletion in the 3'-untranslated region, responsible for deregulation of the cyclin D1 gene in oncogenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9626342     DOI: 10.1002/(sici)1097-0215(19980610)76:6<791::aid-ijc4>3.0.co;2-t

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation.

Authors:  W Wang; M C Caldwell; S Lin; H Furneaux; M Gorospe
Journal:  EMBO J       Date:  2000-05-15       Impact factor: 11.598

Review 2.  Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer.

Authors:  R J Michalides
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

3.  Down-regulation of cyclin D1 expression by prostaglandin A(2) is mediated by enhanced cyclin D1 mRNA turnover.

Authors:  S Lin; W Wang; G M Wilson; X Yang; G Brewer; N J Holbrook; M Gorospe
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

4.  Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs.

Authors:  Ashish Lal; Krystyna Mazan-Mamczarz; Tomoko Kawai; Xiaoling Yang; Jennifer L Martindale; Myriam Gorospe
Journal:  EMBO J       Date:  2004-07-15       Impact factor: 11.598

5.  Cyclin D1 rare variants in UK multiple adenoma and early-onset colorectal cancer patients.

Authors:  Carolina Bonilla; Jérémie H Lefèvre; Bruce Winney; Elaine Johnstone; Susan Tonks; Chrystelle Colas; Tammy Day; Katarzyna Hutnik; Abdelhamid Boumertit; Rachel Midgley; David Kerr; Yann Parc; Walter F Bodmer
Journal:  J Hum Genet       Date:  2010-11-25       Impact factor: 3.172

6.  Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival.

Authors:  Adrian Wiestner; Mahsa Tehrani; Michael Chiorazzi; George Wright; Federica Gibellini; Kazutaka Nakayama; Hui Liu; Andreas Rosenwald; H Konrad Muller-Hermelink; German Ott; Wing C Chan; Timothy C Greiner; Dennis D Weisenburger; Julie Vose; James O Armitage; Randy D Gascoyne; Joseph M Connors; Elias Campo; Emilio Montserrat; Francesc Bosch; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Richard I Fisher; Thomas M Grogan; Thomas P Miller; Wyndham H Wilson; Elaine S Jaffe; Louis M Staudt
Journal:  Blood       Date:  2007-02-13       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.